top of page
Home
Pipeline
Our Team
News
Events
Publications
Careers
Contact
More
Use tab to navigate through the menu items.
News
2024
06/24 Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S.
05/2024 Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10M Award by BARDA
2023
6/25/2023 Shionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex Biopharma, Inc.
2022
10/17/2022 Qpex Biopharma Announces Presentations on Phase 1 and Nonclinical Data
04/21/2022 Qpex Biopharma Announces Presentation of Clinical Data at ECCMID 2022 Meeting
03/30/2022 Qpex Biopharma Announces Publication of Data in Nature Communications
01/19/2022 Qpex Announces Progress on Three Clinical Stage Programs
2021
06/17/2021 Qpex Biopharma Initiates Phase 1 Study of QPX9003
05/12/2021 Qpex Biopharma Initiates Phase 1 Study of ORAvance™
01/05/2021 Qpex Strengthens Leadership Team and Provides Update on BARDA Award
2020
12/03/2020 Qpex Initiates Phase 1 Clinical Trial of QPX7728
2019
12/2019 Qpex Biopharma Announces Exercise of $20 Million Option by BARDA
10/2019 - Qpex Biopharma and Brii Biosciences Enter Into a Strategic Collaboration
09/2019 - Qpex Biopharma to Present its Anti-infective Portfolio at IDWeek 2019
06/2019 - Qpex to Provide First Public Presentations at ASM Microbe Meeting
04/2019 - Qpex Licenses Polymyxin Antimicrobial Program from Monash University
2018
10/2018 - Qpex Biopharma Announces Closing of $33 Million
bottom of page
